SPRY fundamentals
ARS Pharmaceuticals, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of SPRY for the last quarter is 2.07 M USD, and it's 313.60% higher compared to the previous quarter. The net income of Q3 24 is -19.13 M USD.
Q4 '19
Q1 '20
Q2 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q4 '19
Q1 '20
Q2 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM